Efficacy of dichloroacetate as a lactate-lowering drug
- PMID: 12856382
Efficacy of dichloroacetate as a lactate-lowering drug
Abstract
Dichloroacetate (DCA) decreases blood, cerebral spinal fluid, and intracellular lactate concentrations by activating the mitochondrial pyruvate dehydrogenase enzyme complex. The authors reviewed the efficacy of this investigational drug in the treatment of acquired or congenital forms of lactic acidosis from data in 40 English-language publications. The hypolactatemic effect of DCA occurs over a broad range of pretreatment lactate concentrations and is directly related to the baseline lactate level. The maximum lactate-lowering effect of the drug is dependent on its dose but independent of time following its administration. Recent clinical studies of acquired lactic acidosis suggest that DCA could be rapidly effective in reducing this risk factor of mortality in patients with mild hyperlactatemeia.
Similar articles
-
Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children.Pediatrics. 2006 May;117(5):1519-31. doi: 10.1542/peds.2005-1226. Pediatrics. 2006. PMID: 16651305 Clinical Trial.
-
[Dose dependent effects of dichloroacetate on lactic acidosis in dogs].Masui. 1989 Aug;38(8):1005-11. Masui. 1989. PMID: 2810694 Japanese.
-
Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria.QJM. 1995 May;88(5):341-9. QJM. 1995. PMID: 7796089 Clinical Trial.
-
[Sodium dichloroacetate--a substance with manifold therapeutic potential].Wien Klin Wochenschr. 1990 Feb 2;102(3):65-9. Wien Klin Wochenschr. 1990. PMID: 2180210 Review. German.
-
Lactic acidosis update for critical care clinicians.J Am Soc Nephrol. 2001 Feb;12 Suppl 17:S15-9. J Am Soc Nephrol. 2001. PMID: 11251027 Review.
Cited by
-
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology.Front Oncol. 2013 Mar 7;3:38. doi: 10.3389/fonc.2013.00038. eCollection 2013. Front Oncol. 2013. PMID: 23471124 Free PMC article.
-
Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis.Blood Adv. 2018 Aug 14;2(15):2029-2038. doi: 10.1182/bloodadvances.2018022392. Blood Adv. 2018. PMID: 30108111 Free PMC article.
-
Myocardial lactate deprivation is associated with decreased cardiovascular performance, decreased myocardial energetics, and early death in endotoxic shock.Intensive Care Med. 2007 Mar;33(3):495-502. doi: 10.1007/s00134-006-0523-9. Epub 2007 Jan 23. Intensive Care Med. 2007. PMID: 17242933
-
Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.J Biol Chem. 2016 Aug 12;291(33):17405-16. doi: 10.1074/jbc.M116.713735. Epub 2016 Jun 21. J Biol Chem. 2016. Retraction in: J Biol Chem. 2020 Mar 27;295(13):4368. doi: 10.1074/jbc.W120.013237. PMID: 27330076 Free PMC article. Retracted.
-
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.Cancer Lett. 2016 Oct 10;381(1):23-30. doi: 10.1016/j.canlet.2016.07.020. Epub 2016 Jul 19. Cancer Lett. 2016. PMID: 27450723 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources